FOCUS ON: BLADDER CANCER
 
How new agents may address NMIBC treatment challenges
Systemic and intravesical therapies are changing the landscape of BCG-unresponsive disease, according to Matthew Galsky, MD.
Read his article
ADVERTISEMENT
 
Bladder-sparing treatments linked with high rates of progression in NMIBC subset
High-grade nonmuscle-invasive bladder cancer is characterized by high rates of disease progression following introduction of bladder-preservation therapy after treatment with Bacillus Calmette-Guérin.
Learn more
 
ADVERTISEMENT
Your guide to the new colors of Bladder Cancer
Green. Blue. White. Pink. There’s a new spectrum of color in today’s clinical world. The strongest data and expert recommendations clearly support blue and pink with white. Find out why. See how bright pink gives you Confidence at First Sight.
 
 
MORE FROM UROLOGY TIMES
 
Sequential gemcitabine/docetaxel promising for recurrent NMIBC
53% of CIS patients achieve complete response with nadofaragene
 
ADVERTISEMENT
AR-targeted therapies: progress for mCRPC
In this Urology Times® supplement, a roundtable of expert urologists and oncologists addresses common questions about patient evaluation and management of castration-resistant prostate cancer (CRPC) and high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including the role and impact of the commercially available androgen receptor splice variant 7 (AR-V7) test to guide treatment decisions for men with metastatic CRPC. Read it now.
 
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont